Arpad Hasenauer

Dr. Arpad Hasenauer

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AHArpad Hasenauer
Arpad Hasenauer
CFCéline Forster
Céline Forster
JHJohan Hungerbühler
Johan Hungerbühler
JPJean Yannis Perentes
Jean Yannis Perentes
EAEtienne Abdelnour-Berchtold
Etienne Abdelnour-Berchtold
MGMichel Gonzalez
Michel Gonzalez
We aimed to evaluate whether computed tomography (CT)-derived preoperative sarcopenia measures were associated with postoperative outcomes and survival after video-assisted thoracoscopic (VATS) anatomical pulmonary resection in patients with early-stage non-small cell lung cancer (NSCLC). We retrospectively reviewed all consecutive patients that underwent VATS anatomical pulmonary resection for NSCLC between 2012 and 2019. Skeletal muscle mass was measured at L3 vertebral level on preoperative CT or PET/CT scans to identify sarcopenic patients according to established threshold values. We compared postoperative outcomes and survival of sarcopenic vs. non-sarcopenic patients. A total of 401 patients underwent VATS anatomical pulmonary resection for NSCLC. Sarcopenia was identified in 92 patients (23%). Sarcopenic patients were predominantly males (75% vs. 25%; p < 0.001) and had a lower BMI (21.4 vs. 26.5 kg/m2; p < 0.001). The overall postoperative complication rate was significantly higher (53.2% vs. 39.2%; p = 0.017) in sarcopenic patients and the length of hospital stay was prolonged (8 vs. 6 days; p = 0.032). Two factors were associated with postoperative morbidity in multivariate analysis: BMI and American Society of Anesthesiologists score >2. Median overall survival was comparable between groups (41 vs. 46 months; p = 0.240). CT-derived sarcopenia appeared to have a small impact on early postoperative clinical outcomes, but no effect on overall survival after VATS anatomical lung resection for NSCLC.

20 May 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
AOAmaia Ojanguren
Amaia Ojanguren
RPRoumen Parapanov
Roumen Parapanov
ADAnne Debonneville
Anne Debonneville
JLJérôme Lugrin
Jérôme Lugrin
Csaba SzaboCsaba Szabo
Csaba Szabo
LLLucas Liaudet
Lucas Liaudet
Ex-vivo lung perfusion (EVLP) may serve as a platform for the pharmacological repair of lung grafts before transplantation (LTx). We hypothesized that EVLP could also permit non-pharmacological repair through the induction of a heat shock response, which confers stress adaptation via the expression of heat shock proteins (HSPs). Therefore, we evaluated whether transient heat application during EVLP (thermal preconditioning, TP) might recondition damaged lungs before LTx. TP was performed during EVLP (3h) of rat lungs damaged by warm ischemia, by transiently heating (30 min, 41.5°) the EVLP perfusate, followed by LTx (2h reperfusion). We also assessed TP (30 min, 42°) during EVLP (4h) of swine lungs damaged by prolonged cold ischemia. In rat lungs, TP induced HSP expression, reduced NFκB and inflammasome activity, oxidative stress, epithelial injury, inflammatory cytokines, necroptotic death signaling, and the expression of genes involved in innate immune and cell death pathways. After LTx, heated lungs displayed reduced inflammation, edema, histological damage, improved compliance, but unchanged oxygenation. In pig lungs, TP induced HSP expression, reduced oxidative stress, inflammation, epithelial damage, vascular resistance, and ameliorated compliance. Collectively, these data indicate that transient heat application during EVLP promotes significant reconditioning of damaged lungs and improves their outcomes after transplantation.

5 September 2025 in American Journal of Case Reports
Verified
Journal Article
Open access
AHArpad Hasenauer
Arpad Hasenauer
ADAnna Dambrosio
Anna Dambrosio
SHSebastian Happ
Sebastian Happ
MCMichel Christodoulou
Michel Christodoulou
BACKGROUND Chest wall hernia and residual pleural space are known complications after thoracoscopic anatomical lung resection. Some risk factors for chest wall hernia have been described; however, residual pleural space has never been described as one of them. We present 2 cases suggesting that postoperative residual air space can represent a newly identified risk factor for chest wall hernia. CASE REPORT Case 1: A 71-year-old man developed a postoperative chest wall hernia at the fourth intercostal incision level 1 week after a 3-port thoracoscopic left lower lobectomy for early-stage non-small cell lung carcinoma. He was not known to have any described risk factors for postoperative chest wall hernia, but his postoperative course was complicated by a residual pleural space. Case 2: A 60-year-old man developed a postoperative chest wall hernia at the fourth intercostal incision level, diagnosed 5 months after a right apical upper lobe segmentectomy by 3-port thoracoscopy for early-stage non-small cell lung carcinoma. She was not known to have any risk factors for postoperative chest wall hernia; however, her postoperative course was also complicated by a residual pleural space. CONCLUSIONS We suggest that air flow through the thoracoscopic incision, due to residual pleural air, could impede wound healing and favor chest wall hernia. Adaptation of the closure technique for video-assisted thoracic surgery incisions in patients at risk may help prevent postoperative chest wall hernias. These cases highlight the possibility that residual pleural space could be a newly identified risk factor for postoperative chest wall hernia and propose potential preventive measures.

1 September 2021 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
COCaroline Olt
Caroline Olt
KFKathleen Faulkenberg
Kathleen Faulkenberg
EHEileen Hsich
Eileen Hsich
RGReda E Girgis
Reda E Girgis
MHMarius Hoeper
Marius Hoeper
LLLucas Liaudet
Lucas Liaudet

31 May 2022 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
AHArpad Hasenauer
Arpad Hasenauer
JHJ Hungerbühler
J Hungerbühler
JPJ Perentes
J Perentes
EAE Abdelnour
E Abdelnour
JKJ Koerfer
J Koerfer
MGM Gonzalez
M Gonzalez
Objective: Sarcopenia is defined by a progressive loss of skeletal muscle mass and strength, combined with muscle fatty infiltration. Lung cancer patients frequently suffer from sarcopenia which may be associated with poorer post-operative outcomes. The aim of this study is to evaluate whether preoperative CT-based sarcopenia was associated with postoperative outcomes and survival after VATS resections in patients with early-stage non-small cell lung cancer (NSCLC). Methods: We retrospectively reviewed all consecutive patients that underwent anatomical resection for NSCLC between 2012 and 2019. The skeletal muscle index (SMI) and muscle quality (SMRA and IMAT) were measured at the L3 vertebral level on preoperative CT or PET/CT scans. We used the following SMI cut-off values for sarcopenia: 52.4 cm2 /m2 for men and 38.5 cm2 /m2 for women. Results: In total, 401 patients (sex ratio F/M: 173/228, mean age: 67 +/- 9.3 years) underwent VATS lobectomies (n=304) and segmentectomies (n=97) for NSCLC. Overall morbidity and mortality were 42.4% and 0.2%, respectively. The median length of stay was 7 days (IQR: 4–10). Sarcopenia was identified in 92 patients (23%). Patients with sarcopenia were predominantly males (75% vs 25%, p<0.001) and had lower BMI (21.4 vs 26.5, p2 remained associated with increased morbidity on multivariate analysis. The median overall survival was comparable between patients with sarcopenia and those without sarcopenia (41 vs. 46 months, p=0.240). Conclusion: Based on CT assessment alone, preoperative sarcopenia appeared to have little impact on postoperative clinical outcomes or overall survival in patients undergoing VATS pulmonary resection. Further studies should also consider muscle strength and physical performance, in addition to CT imaging, for preoperative risk assessment.

10 January 2026 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
EAEtienne Abdelnour-Berchtold
Etienne Abdelnour-Berchtold
LCLouis-Emmanuel Chriqui
Louis-Emmanuel Chriqui
LZLaetitia Zermatten
Laetitia Zermatten
SPSotirios Papadopoulos
Sotirios Papadopoulos
CFCeline Forster
Celine Forster
JPJean Yannis Perentes
Jean Yannis Perentes
Immunotherapy (IO) has been associated with better outcomes in locally advanced non-small cell lung cancers (NSCLCs). In 2017, our center introduced compassionate use of immunotherapy for stage III NSCLC as follows: neoadjuvant chemotherapy combined to perioperative immunotherapy and surgery for resectable NSCLCs (PERIOPERATIVE) and chemo-radiation therapy followed by immunotherapy (PACIFIC) for non-resectable NSCLCs. We report the outcomes and complications of 78 patients. IWe reviewed all stage III NSCLC patients treated in the Center or Thoracic Surgery of Romandie (CURCT) between 2017 and 2023 with chemo-immunotherapy and surgery and radiation therapy using our prospectively collected database. We compared groups using Stata®. Intention to treat population consisted in 52 PERIOPERATIVE and 26 PACIFIC patients. PERIOPERATIVE patients were significantly younger (64 [60-71]vs73 [67-80], p = 0.0001) and had better lung diffusion capacity compared to PACIFIC patients (%predicted DLCO: 74 ± 18vs48 ± 26, p = 0.0008). Complications over the course of therapy occurred in more than 50 % of patients but remained manageable in both groups. Forty-two of 52 PERIOPERATIVE (81 %) and 18 of 26 (69 %) PACIFIC patients completed the entire treatment plan. There was no 30-day mortality. Complete pathological response (pCR) occurred in 11 of the 50 operated PERIOPERATIVE patients (22 %) and was associated with a 100 % 5-year survival. Overall, 5-year survival was of 78 % and 30 % in the PERIOPERATIVE and PACIFIC groups respectively. The inclusion of immunotherapy in the management of stage III NSCLC has been associated with improved patient outcomes. Real life data suggests that patient complications are frequent but manageable and that patient dropout is low.